Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers in this study are exploring the feasibility of making an immunotherapy in a laboratory using white blood cells (called lymphocytes or T cells) collected from the tumor of a patient with metastatic uveal melanoma. This is called autologous tumor-infiltrating lymphocyte (TIL) therapy. The TIL therapy being assessed in this study is called LN-144, and it is designed to activate white blood cells to attack the tumor.
Researchers are assessing the combination of teclistamab and mezigdomide to treat multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing after treatment.
Researchers want to find the best dose of 225Ac-ABD147 to treat advanced lung cancer. The people in this study have small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma of the lung (LCNEC). Their cancer keeps growing even after treatment that included platinum-based chemotherapy.
Metaiodobenzylguanidine (MIBG) is a substance taken up specifically by neuroblastoma, pheochromocytoma, or paraganglioma tumor cells. MIBG can be combined with radioactive iodine (<sup>131</sup>I) in the laboratory to form the radioactive compound <sup>131</sup>I-MIBG. The <sup>131</sup>I-MIBG compound concentrates more in cancer cells than in normal cells. It may therefore deliver more radiation directly to cancer cells while sparing normal organs.
Ruxolitinib is used to treat myelofibrosis, a rare bone marrow cancer that disrupts your body's normal blood cell production. Some people taking this drug, however, keep having symptoms. Researchers want to see if adding the drug ulixertinib to ruxolitinib treatment is safe and works better to treat myelofibrosis.
Researchers want to find the best dose of BMS-986504 to use safely in people with lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that spread beyond its original location. In addition, their tumors are missing the MTAP gene.
Chronic graft-versus-host disease (cGVHD) is a condition in which healthy transplanted stem cells attack the recipient's healthy cells. cGVHD most often happens more than 100 days after a stem cell transplant, but it can happen at any time.
When vulvar cancer is removed, surgeons examine the first lymph nodes to which cancer might spread ("sentinel lymph nodes") to see if they contain cancer cells. If the sentinel lymph nodes contain cancer, the usual treatment is more surgery to remove all of the lymph nodes in the groin, followed by several weeks of radiation therapy to reduce the chance that the cancer will come back. However, removing all of the lymph nodes increases the risk of lymphedema, which causes uncomfortable swelling in the legs, as well as an elevated risk of infection.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Intensity-modulated pleural radiation therapy (IMPRINT) is a type of radiation therapy that specifically targets the lining of the lungs and the inner side of the ribs to stop cancer from growing. In this study, researchers are studying the safety and effectiveness of IMPRINT to one side of the chest (hemithoracic IMPRINT) to treat people with thymic cancer (cancer of the thymus gland) that has spread to the lining of the lungs and chest.
